To read the full story, subscribe or sign in.

China financings pick up: Everest’s $200M placement, Leads’ $189M IPO

July 29, 2025

Chinese financings are picking up, with Everest Medicines Ltd. raising US$200 million and Nanjing-based Leads Bioloabs Co. Ltd. listing on the main board of the Hong Kong Stock Exchange in a $189 million IPO.

BioWorld Asia Financings Cancer Immune IPO Asia-Pacific China

Bio Korea 2026 kicks off with spotlight on oligonucleotides

BioWorld

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...

AA meeting of minds as PTC, Novartis push votoplam in HD

BioWorld

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...

Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

BioWorld Science

Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.

Glucagon-like peptide-1 receptor (GLP-1R) complex

Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

BioWorld

A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...